Differential Toxicity of Immune Checkpoint Inhibitors in Older Adults: A Large-Scale, Propensity Score-Matched Real-World Analysis

Key Points

• This research investigates the survival outcomes and toxicity profiles of immune checkpoint inhibitors in older adults aged 75 and above.
• Conducted a large-scale real-world analysis of patients aged ≥75 years
• Utilized propensity score matching to compare outcomes
• Assessed incidence and types of immune-related adverse events (irAEs)
• Older adults exhibited poorer survival rates compared to younger counterparts
• Lower overall incidence of irAEs was observed in the older population
• Increased risk of specific, highly morbid toxicities was noted uniquely in older adults